Tower Research Capital LLC (Trc) Gemini Therapeutics, Inc. Transaction History

Tower Research Capital LLC (Trc)

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$1.31 - $2.01 $9,600 - $14,731	-7,329 Reduced 93.52%	508 $1,000
Q2 2022 Aug 15, 2022	SELL	$1.22 - $1.73 $647 - $918	-531 Reduced 6.35%	7,837 $13,000
Q1 2022 May 12, 2022	SELL	$1.29 - $3.08 $18,662 - $44,558	-14,467 Reduced 63.35%	8,368 $12,000
Q4 2021 Feb 14, 2022	BUY	$2.39 - $4.0 $49,253 - $82,432	20,608 Added 925.37%	22,835 $66,000
Q3 2021 Nov 15, 2021	SELL	$3.3 - $6.32 $5,900 - $11,300	-1,788 Reduced 44.53%	2,227 $9,000
Q2 2021 Aug 16, 2021	BUY	$6.32 - $14.02 $25,374 - $56,290	4,015 New	4,015 $26,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.